4D Molecular Therapeutics Inc
FDMTHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET
12.12-0.88 (-6.74%)
2026-11-13 13:06 CET
Market cap
$669.28M
Revenue, TTM
96.06 USD m
Net income, TTM
-200.35 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-2.79
Price
FDMT against its 20, 50 and 200-day averagesPatternshover a marker to name it
28.4% under the 52-week high of 16.93 on 19 Aug 2026. 52-week low 6.96 on 5 Jan 2026. Last 15 sessions, 26.7% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 76
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 5 of 6 — fails: 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 2 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Performance: Year +50%
Accumulation 4 of 4
Relative Strength 2 of 3 — fails: Performance: Year +100%
Profile
FDMT52-week range, 52% of the way up
6.9616.93
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
| Index | RUT |
|---|---|
| Employees | 196 |
| IPO | Dec 11, 2020 |
| Beta | 2.91 |
| ATR, 14d | 0.91 |
| Rel volume | 0.00 |
| Short float | 21.59% |
| Insider own | 8.62% |
| Inst own | 99.14% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $669.28M |
| Enterprise Value | 333.47M |
| Income | -200.35M |
| Sales | 96.06M |
| Book / share | 7.38 |
| Cash / share | 6.79 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 196 |
| IPO | Dec 11, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 6.97 |
| Price / book | 1.64 |
| Price / cash | 1.78 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 3.47 |
| Quick Ratio | 8.03 |
| Current Ratio | 8.03 |
| Debt / equity | 0.12 |
| Long-term debt / equity | 0.10 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -2.79 |
|---|---|
| Earnings next year | -4.10 |
| Earnings next quarter | -1.07 |
| Earnings this year | -71.75% |
| Earnings next year | 1.40% |
| Earnings growth, 5 years | -15.73% |
| Past earnings growth | 10.05% -2.62% |
| Past sales growth | 200.86% 44.32% |
| Earnings vs last year | 26.59% |
| Sales vs last year | 79952.50% |
| Earnings vs last quarter | -6.60% |
| Sales vs last quarter | 4505.56% |
| Earnings | Nov 12 AMC |
| Surprise | -2.85% 0.28% |
Ownership
| Insiders own | 8.62% |
|---|---|
| Insider trades | -8.05% |
| Institutions own | 99.14% |
| Institution trades | 17.18% |
| Return on assets | -46.99% |
| Return on equity | -56.68% |
| Return on capital | -45.38% |
| Gross Margin | 87.32% |
| Operating margin | -226.05% |
| Profit Margin | -208.57% |
| 20-day average | -0.10% |
| 50-day average | -8.14% |
| 200-day average | 9.54% |
Technical
| Shares out | 55.24M |
|---|---|
| Shares floating | 50.48M |
| Short / float | 21.59% |
| Short ratio | 10.28 |
| Short interest | 10.90M |
| 52-week high | 16.93 -28.4% |
| 52-week low | 6.96 +74.1% |
| Volatility | 6.63% 7.88% |
| Average range | 0.91 |
| Strength index | 47.58 |
| Market sensitivity | 2.91 |
| Relative volume | 0.00 |
| Avg Volume | 1.06M |
| Volume | 0 |
Performance
| Perf Week | 7.69% |
|---|---|
| Perf Month | -0.70% |
| Perf Quarter | -0.62% |
| Perf Half Y | 23.50% |
| Perf YTD | 61.53% |
| Perf Year | 10.44% |
| Perf 3Y | 9.64% |
| Perf 5Y | -51.50% |
| Perf 10Y | - |
| Recommendation | 1.25 |
| Target Price | 28.09 |
| Prev Close | 12.11 |
| Price | 12.11 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 14, 2026 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | $20 | +65.1% |
| Jul 31, 2026 | Initiated | B. Riley Securities | Buy | $37 | +205.4% |
| Jan 28, 2026 | Resumed | Barclays | Overweight | $33 | +172.4% |
| Nov 07, 2025 | Upgrade | Morgan Stanley | Underweight → Equal-Weight | ||
| Jan 13, 2025 | Downgrade | BMO Capital Markets | Outperform → Market Perform | $40 → $15 | +23.8% |
| Nov 21, 2024 | Initiated | Morgan Stanley | Underweight | $8 | -34.0% |
| Sep 23, 2024 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | ||
| Apr 15, 2024 | Initiated | Barclays | Overweight | $459 | +3,688.7% |
| Apr 15, 2024 | Initiated | Barclays | Overweight | $45 | +271.4% |
| Feb 07, 2024 | Resumed | Goldman | Buy | $81 | +568.6% |
Peers
Mkt capInsider trading
latest 14 of 44| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer | Oct 16 '26 | Option Exercise | 4.14 | 1,635 | 6,769 | 10,252 | Oct 20 04:56 PM |
| Bizily Scott | Chief Legal Officer | Oct 16 '26 | Sale | 12.84 | 1,635 | 20,993 | 8,617 | Oct 20 04:56 PM |
| Kirn David | See Remarks | Oct 05 '26 | Sale | 12.92 | 58,333 | 753,937 | 709,153 | Oct 07 05:11 PM |
| David Kirn | Officer | Oct 05 '26 | Proposed Sale | 12.92 | 58,333 | 753,662 | Oct 05 06:23 PM | |
| Bizily Scott | Chief Legal Officer | Sep 16 '26 | Option Exercise | 4.14 | 1,635 | 6,769 | 10,252 | Sep 22 06:43 PM |
| Bizily Scott | Chief Legal Officer | Sep 16 '26 | Sale | 13.65 | 1,635 | 22,318 | 8,617 | Sep 22 06:43 PM |
| Kirn David | See Remarks | Sep 14 '26 | Sale | 13.90 | 58,333 | 811,004 | 767,486 | Sep 16 05:13 PM |
| David Kirn | Officer | Sep 14 '26 | Proposed Sale | 13.76 | 58,333 | 802,662 | Sep 14 06:00 PM | |
| Bizily Scott | Chief Legal Officer | Sep 01 '26 | Option Exercise | 6.49 | 584 | 3,790 | 9,201 | Sep 03 06:55 PM |
| Bizily Scott | Chief Legal Officer | Sep 01 '26 | Sale | 14.00 | 584 | 8,176 | 8,617 | Sep 03 06:55 PM |
| Kirn David | See Remarks | Aug 19 '26 | Option Exercise | 4.14 | 50,000 | 207,000 | 894,895 | Aug 21 04:06 PM |
| Kirn David | See Remarks | Aug 19 '26 | Sale | 15.75 | 69,076 | 1,088,273 | 825,819 | Aug 21 04:06 PM |
| David Kirn | Officer | Aug 19 '26 | Proposed Sale | 16.76 | 69,076 | 1,157,714 | Aug 19 06:28 PM | |
| Bizily Scott | Chief Legal Officer | Aug 13 '26 | Option Exercise | 4.14 | 1,635 | 6,769 | 10,252 | Aug 17 05:34 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | AUM: 2.54B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
News
latest 14 of 200- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire) -6.74%
- 4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.10%
- 4DMT Announces New Employment Inducement Grants (GlobeNewswire) -5.67%
- 4DMT to Host Investor Day on October 21, 2026 (GlobeNewswire) -5.49%
- This is the top biotech stock pick from B Riley Securities (Investing.com)
- OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits)
- 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME (GlobeNewswire)
- 4DMT Announces New Employment Inducement Grants (GlobeNewswire)
- 4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
- OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits) +19.32%
- 4DMT Announces New Employment Inducement Grants (GlobeNewswire)
- 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
- Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls (The Fly)
- 10 Stock Picks to Celebrate 45 Years of Schaeffer's (Schaeffer's Research)
Quarterly earnings
2026Q3 EPS -1.080 missed -1.050, from -1.010 a year earlier. Sales 4.15 beat 4.13, from 0.09 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 16:30 | -1.080 | -1.050 | -1.080 | 4.15 | 4.13 | EPS +2.8% · sales +0.3% | vs 2025Q3, year-ago quarter · EPS +6.9% · sales +4505.6% | 11 EPS · 6 sales | - |
| 2026Q2ended 2026-06-30 | 2026-08-13 16:30 | -1.040 | -1.017 | -1.038 | 3.78 | 3.62 | EPS +2.3% · sales +4.4% | vs 2025Q2, year-ago quarter · EPS +6.1% · sales +25106.7% | 9 EPS · 6 sales | Open -0.17% vs SPY +0.08%. Close +4.64% vs SPY -0.20% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -1.010 | -0.996 | -1.010 | 3.05 | 2.59 | EPS +1.4% · sales +17.8% | vs 2025Q1, year-ago quarter · EPS +17.4% · sales +50683.3% | 9 EPS · 6 sales | Open -8.56% vs SPY +0.46%. Close +2.11% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-03-18 16:30 | 0.430 | -0.528 | 0.337 | 85.10 | 27.00 | EPS -181.4% · sales +215.2% | vs 2024Q4, year-ago quarter · EPS -148.3% · sales +1309115.4% | 10 EPS · 8 sales | Open +16.12% vs SPY -0.67%. Close +4.91% vs SPY -0.25% |
| 2025Q3ended 2025-09-30 | 2025-11-10 08:30 | -1.010 | -0.983 | -1.013 | 0.09 | 0.29 | EPS +2.8% · sales -68.7% | vs 2024Q3, year-ago quarter · EPS +27.8% · sales +2900.0% | 10 EPS · 7 sales | Open -1.43% vs SPY +0.93%. Close -3.14% vs SPY +1.56% |
| 2025Q2ended 2025-06-30 | 2025-08-11 08:30 | -0.980 | -0.727 | -0.977 | 0.02 | 0.39 | EPS +34.7% · sales -96.2% | vs 2024Q2, year-ago quarter · EPS +55.6% · sales +200.0% | 11 EPS · 8 sales | Open -0.18% vs SPY +0.04%. Close -1.78% vs SPY -0.20% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -0.860 | -0.871 | -0.861 | 0.01 | 0.46 | EPS -1.2% · sales -98.7% | vs 2024Q1, year-ago quarter · EPS +30.3% · sales -42.9% | 10 EPS · 7 sales | Open +0.31% vs SPY +0.25%. Close -4.94% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-02-28 08:30 | -0.890 | -0.836 | -1.085 | 0.01 | 1.42 | EPS +6.5% · sales -99.5% | vs 2023Q4, year-ago quarter · EPS +29.0% · sales -136.1% | 11 EPS · 9 sales | Open -0.67% vs SPY +0.09%. Close +1.12% vs SPY +1.56% |
| 2024Q3ended 2024-09-30 | 2024-11-13 16:30 | -0.790 | -0.676 | -0.789 | 0.00 | 1.62 | EPS +16.9% · sales -99.8% | vs 2023Q3, year-ago quarter · EPS +229.2% · sales -100.0% | 10 EPS · 9 sales | Open +2.08% vs SPY +0.02%. Close +4.02% vs SPY -0.64% |
| 2024Q2ended 2024-06-30 | 2024-08-08 16:30 | -0.630 | -0.684 | -0.632 | 0.01 | 1.27 | EPS -7.9% · sales -99.6% | vs 2023Q2, year-ago quarter · EPS -18.2% · sales -97.9% | 10 EPS · 9 sales | Open +6.45% vs SPY -0.16%. Close +0.48% vs SPY +0.44% |
| 2024Q1ended 2024-03-31 | 2024-05-09 16:30 | -0.660 | -0.741 | -0.658 | 0.01 | 1.45 | EPS -10.9% · sales -99.3% | vs 2023Q1, year-ago quarter · EPS -25.0% · sales -96.5% | 10 EPS · 8 sales | Open -1.76% vs SPY +0.32%. Close +0.23% vs SPY +0.13% |
| 2023Q4ended 2023-12-31 | 2024-02-29 16:30 | -0.690 | -0.726 | -0.820 | -0.02 | 2.40 | EPS -5.0% · sales -100.8% | vs 2022Q4, year-ago quarter · EPS -17.9% · sales -101.5% | 10 EPS · 7 sales | Open +2.68% vs SPY +0.18%. Close +4.82% vs SPY +0.94% |
| 2023Q3ended 2023-09-30 | 2023-11-09 16:30 | -0.240 | -0.613 | -0.243 | 20.20 | 8.07 | EPS -60.9% · sales +150.5% | vs 2022Q3, year-ago quarter · EPS -69.6% · sales +3940.8% | 10 EPS · 8 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-09 16:30 | -0.770 | -0.784 | -0.773 | 0.24 | 0.85 | EPS -1.8% · sales -71.8% | vs 2022Q2, year-ago quarter · EPS -11.5% · sales +47.5% | 8 EPS · 6 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-10 16:30 | -0.880 | -0.893 | -0.877 | 0.30 | 1.29 | EPS -1.5% · sales -76.8% | vs 2022Q1, year-ago quarter · EPS +7.3% · sales -75.6% | 6 EPS · 4 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-15 16:30 | -0.840 | -0.786 | -0.843 | 1.22 | 0.87 | EPS +6.9% · sales +39.7% | vs 2021Q4, year-ago quarter · EPS 0.0% · sales +1170.8% | 7 EPS · 5 sales | - |
Annual earnings
2025FY EPS -2.420 beat -3.259, from -2.980 a year earlier. Sales 85.21 beat 33.54, from 0.04 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -1.263 | - | - | 409.39 | - |
| 2029FYestimate | - | -2.875 | - | - | 195.01 | - |
| 2028FYestimate | - | -3.752 | - | - | 46.16 | - |
| 2027FYestimate | - | -4.098 | - | - | 17.89 | - |
| 2026FYestimate | - | -4.156 | - | - | 13.25 | - |
| 2025FY | -2.420 | -3.259 | -2.420 | 85.21 | 33.54 | - |
| 2024FY | -2.980 | -2.909 | -2.982 | 0.04 | 1.28 | - |
| 2023FY | -2.580 | -2.607 | -2.577 | 20.72 | 22.61 | - |
| 2022FY | -3.320 | -3.173 | -3.323 | 3.10 | 2.63 | - |
| 2021FY | -2.570 | -2.783 | -2.572 | 18.04 | 18.83 | - |
| 2020FY | -6.973 | -2.637 | -2.125 | 13.81 | 15.21 | - |
Quarterly results
2026Q3 revenue 4.14, from 0.09 a year earlier. Operating margin -1,962%, from -67,989% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -4.16 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-13 | -4.16 | 0.0% |
| 2026Q4 | E | per share | 2026-11-13 | -1.07 | 0.0% |
| 2026Q4 | R | per share | 2026-11-13 | -1.06 | 0.0% |
| 2026FY | S | per share | 2026-11-13 | 13.25 | 0.0% |
| 2026Q4 | S | per share | 2026-11-13 | 5.17 | 0.0% |
| 2026Q3 | E | per share | 2026-10-28 | -1.05 | 0.0% |
| 2026Q3 | S | per share | 2026-10-28 | 4.13 | 0.0% |
| 2026FY | R | per share | 2026-09-10 | -4.16 | +1.0% |
| 2026Q3 | R | per share | 2026-09-10 | -1.06 | +1.1% |
| 2026Q2 | E | per share | 2026-07-30 | -1.02 | 0.0% |
| 2026Q2 | S | per share | 2026-07-24 | 3.62 | -2.8% |
| 2026Q2 | R | per share | 2026-07-22 | -1.03 | 0.0% |
| 2026Q1 | S | per share | 2026-04-13 | 2.59 | -16.7% |
| 2026Q1 | E | per share | 2026-04-01 | -1.00 | -0.8% |
| 2026Q1 | R | per share | 2026-04-01 | -0.95 | -2.1% |
| 2025FY | E | per share | 2026-03-18 | -3.18 | 0.0% |
| 2025Q4 | E | per share | 2026-03-18 | -0.54 | 0.0% |
| 2025FY | R | per share | 2026-03-18 | -3.30 | 0.0% |
| 2025Q4 | R | per share | 2026-03-18 | -0.45 | 0.0% |
| 2025FY | S | per share | 2026-03-18 | 38.70 | 0.0% |
| 2025Q4 | S | per share | 2026-03-18 | 38.62 | 0.0% |
| 2025Q3 | E | per share | 2025-11-07 | -0.98 | -0.2% |
| 2025Q3 | R | per share | 2025-10-29 | -1.05 | 0.0% |
| 2025Q3 | S | per share | 2025-10-25 | 0.29 | 0.0% |
| 2025Q2 | S | per share | 2025-07-31 | 0.39 | -0.1% |
| 2025Q2 | E | per share | 2025-07-23 | -0.73 | 0.0% |
| 2025Q2 | R | per share | 2025-07-01 | -0.40 | +0.6% |
| 2025Q1 | E | per share | 2025-04-11 | -0.87 | +0.1% |
| 2025Q1 | S | per share | 2025-03-25 | 0.46 | -30.7% |
| 2025Q1 | R | per share | 2025-03-10 | -0.87 | - |
| 2024FY | R | per share | 2025-03-01 | -3.02 | 0.0% |
| 2024Q4 | R | per share | 2025-03-01 | -0.84 | 0.0% |
| 2024FY | E | per share | 2025-02-27 | -2.91 | +0.3% |
| 2024Q4 | E | per share | 2025-02-27 | -0.84 | +0.9% |
| 2024FY | S | per share | 2025-02-27 | 1.28 | -7.2% |
| 2024Q4 | S | per share | 2025-02-27 | 1.42 | -7.3% |
| 2024Q3 | E | per share | 2024-10-23 | -0.68 | 0.0% |
| 2024Q3 | R | per share | 2024-10-23 | -0.67 | 0.0% |
| 2024Q3 | S | per share | 2024-10-23 | 1.62 | 0.0% |
| 2024Q2 | E | per share | 2024-08-03 | -0.68 | 0.0% |
| 2024Q2 | S | per share | 2024-08-03 | 1.27 | 0.0% |
| 2024Q2 | R | per share | 2024-07-24 | -0.75 | 0.0% |
| 2024Q1 | E | per share | 2024-04-19 | -0.74 | -2.1% |
| 2024Q1 | S | per share | 2024-04-19 | 1.45 | +58.2% |
| 2024Q1 | R | per share | 2024-03-28 | -0.74 | +8.1% |
| 2023FY | S | per share | 2024-02-09 | 22.61 | +0.0% |
| 2023FY | E | per share | 2024-02-07 | -2.61 | +0.2% |
| 2023FY | R | per share | 2024-01-27 | -2.65 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.451 | -0.384 | -1.861 | -2.125 | -2.572 | -3.323 | -2.577 | -2.982 | -2.419 | -2.7918 | - |
| Sales USD millions | 6 | 14 | 7 | 14 | 18 | 3 | 21 | 0 | 85 | 96 | - |
| Shares million shares | 25 | 25 | 26 | 27 | 32 | 33 | 43 | 46 | 58 | - | 55 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.789 | -1.085 | -0.861 | -0.977 | -1.013 | 0.337 | -1.01 | -1.038 | -1.08 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 85 | 3 | 4 | 4 |
| Shares million shares | 52 | 46 | 46 | 47 | 47 | 58 | 52 | 55 | - |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 96.06 | 85.21+212925.0% | 0.04-99.8% | 20.72+562.0% | 3.13-82.6% | 18.04+32.5% | 13.61+94.7% | 6.99-50.5% | 14.13 |
| Cost of Goods Sold Incl. D&A | - | 7.62+13.6% | 6.71+16.7% | 5.75+48.2% | 3.88+28.5% | 3.02 | - | - | - |
| Gross Profit | - | 77.58 | -6.67-144.6% | 14.97 | -0.75-105.0% | 15.02 | - | - | - |
| Selling, General and Administrative Excl. Other | 307.09 | 237.13+30.9% | 181.17+41.7% | 127.84+17.0% | 109.28+26.6% | 86.35+25.5% | 68.83+33.4% | 51.61+116.6% | 23.83 |
| Research and Development | 260.65 | 195.70+38.5% | 141.30+45.5% | 97.10+21.0% | 80.25+30.8% | 61.36+15.7% | 53.04+37.0% | 38.72+110.9% | 18.36 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -217.15 | -159.55 | -187.84 | -112.87 | -110.03 | -71.33 | -56.66 | -45.63 | -10.40 |
| Interest Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | - | -0.05-225.0% | 0.04-75.0% | 0.16 | -0.00 | -0.09 | -0.02-100.4% | 5.10 | -0.01 |
| Net Income Before Taxes | -200.35 | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | -9.55 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -200.35 | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | -9.55 |
| Net Income From Continuing Operations | -200.35 | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | -9.55 |
| Net Income | -200.35 | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | -9.55 |
| EPS (Recurring) per share | -2.77 | -2.42 | -2.98 | -2.57 | -3.32 | -2.57 | -2.13 | -1.73 | -0.38 |
| EPS (Basic, Before Extraordinaries) per share | -2.79 | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | -2.12 | -1.86 | -0.38 |
| EPS (Diluted) per share | -2.79 | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | -2.12 | -1.86 | -0.38 |
| EBITDA | - | -151.92 | -181.14 | -107.12 | -106.15 | -68.31 | -55.22 | -44.62 | -9.70 |
| Non-Operating Income (Expense) | 2.97 | 19.39-28.2% | 27.01+121.6% | 12.19+379.9% | 2.54 | -0.08 | -0.05-103.5% | 1.42+71.1% | 0.83 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 22.02-15.7% | 26.12+32.9% | 19.66+14.8% | 17.12+24.1% | 13.80+177.1% | 4.98+40.7% | 3.54+156.5% | 1.38 |
| Price To Sales Ratio ratio | - | 5.10 | 8,120.72 | 38.26 | 229.63 | 33.73 | 81.25 | - | - |
| Gross Margin % | - | 91.05 | -18,021.62 | 72.26 | -24.00 | 83.26 | - | - | - |
| Operating Margin % | -226.05 | -187.24 | -507,678.38 | -544.65 | -3,516.52 | -395.46 | -416.28 | -653.12 | -73.60 |
| Net Margin % | -208.57 | -164.43 | -434,778.38 | -486.59 | -3,435.41 | -395.37 | -416.49 | -705.78 | -67.59 |
| Shares Outstanding million shares | - | 57.61+25.8% | 45.79+6.3% | 43.08+32.0% | 32.63+1.3% | 32.22+20.8% | 26.68+0.7% | 26.49+6.5% | 24.88 |
| Market Capitalization | 669.28 | 669.28+159.9% | 257.49-70.3% | 866.19+20.4% | 719.44+2.0% | 705.13-35.8% | 1,098.16-0.5% | 1,103.20 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.14+4500.0% | 3.78+37700.0% | 3.05+30400.0% | 85.09 | 0.09 | 0.010.0% | 0.01-66.7% | 0.00 |
| Cost of Goods Sold Incl. D&A | - | 2.09+10.6% | 2.06+17.7% | 1.98+11.2% | 2.00+17.6% | 1.89+16.7% | 1.75+10.1% | 1.78 |
| Gross Profit | - | 1.69 | 0.99 | 83.11 | -1.91 | -1.87 | -1.74 | -1.78 |
| Selling, General and Administrative Excl. Other | 85.36+44.0% | 78.72+36.7% | 74.61+43.8% | 68.39+25.9% | 59.27+19.9% | 57.58+41.0% | 51.88+41.9% | 54.33 |
| Research and Development | 69.78+41.1% | 68.28+42.4% | 64.98+59.7% | 57.61+33.7% | 49.44+28.5% | 47.95+50.5% | 40.70+46.0% | 43.09 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -81.22 | -77.03 | -73.62 | 14.71 | -61.19 | -59.46 | -53.62 | -56.12 |
| Interest Expense | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | - | -0.01-200.0% | - | 0.010.0% | 0.010.0% | 0.010.0% | -0.09 | 0.01 |
| Net Income Before Taxes | -78.06 | -72.94 | -68.76 | 19.40 | -56.88 | -54.66 | -47.97 | -49.67 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -78.06 | -72.94 | -68.76 | 19.40 | -56.88 | -54.66 | -47.97 | -49.67 |
| Net Income From Continuing Operations | -78.06 | -72.94 | -68.76 | 19.40 | -56.88 | -54.66 | -47.97 | -49.67 |
| Net Income | -78.06 | -72.94 | -68.76 | 19.40 | -56.88 | -54.66 | -47.97 | -49.67 |
| EPS (Recurring) per share | -1.08 | -1.04 | -1.01 | 0.34 | -1.01 | -0.98 | -0.86 | -1.08 |
| EPS (Basic, Before Extraordinaries) per share | -1.08 | -1.04 | -1.01 | 0.34 | -1.01 | -0.98 | -0.86 | -1.08 |
| EPS (Diluted) per share | -1.08 | -1.04 | -1.01 | 0.34 | -1.01 | -0.98 | -0.86 | -1.08 |
| EBITDA | - | -74.94 | -71.56 | 16.70 | -59.18 | -57.57 | -51.87 | -54.33 |
| Non-Operating Income (Expense) | 3.16-26.9% | 4.08-15.2% | 4.86-12.6% | 4.70-27.2% | 4.32-40.8% | 4.81-36.0% | 5.56-3.1% | 6.46 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 5.88+18.5% | 4.45-36.3% | 5.55-26.8% | 4.52-30.4% | 4.96-18.3% | 6.99+17.1% | 7.58 |
| Price To Sales Ratio ratio | - | 10.16 | 7.18 | 5.07 | 4,064.48 | 6,287.56 | 7,828.40 | 6,893.84 |
| Gross Margin % | - | 44.75 | 32.56 | 97.67 | -2,125.56 | -12,486.67 | -12,428.57 | -178,300.00 |
| Operating Margin % | -1,959.42 | -2,037.16 | -2,416.15 | 17.29 | -67,983.33 | -396,373.33 | -383,007.14 | - |
| Net Margin % | -1,883.14 | -1,929.01 | -2,256.65 | 22.80 | -63,195.56 | -364,386.67 | -342,657.14 | - |
| Shares Outstanding million shares | - | 55.21+18.2% | 52.27+12.8% | 57.61+25.8% | 46.77-10.1% | 46.70-10.0% | 46.32-9.5% | 45.79 |
| Market Capitalization | 669.28+64.9% | 695.27+304.6% | 475.29+217.8% | 428.51+66.4% | 405.84-27.8% | 171.86-84.2% | 149.56-90.6% | 257.49 |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 402.65-5.2% | 424.88+47.4% | 288.23+35.0% | 213.55-13.8% | 247.78-10.5% | 276.73+457.4% | 49.65-45.9% | 91.76+284.7% | 23.85 |
| Short Term Receivables | 0.00 | 0.00 | 0.00-100.0% | 0.70+1300.0% | 0.05-96.6% | 1.49+52.0% | 0.98-12.5% | 1.12+250.0% | 0.32 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 10.48+4.3% | 10.05+20.2% | 8.36+33.5% | 6.26-26.0% | 8.46+90.5% | 4.44+136.2% | 1.88+59.3% | 1.18+257.6% | 0.33 |
| Total Current Assets | 413.13-5.0% | 434.93+46.6% | 296.59+34.5% | 220.51-14.0% | 256.28-9.3% | 282.66+438.3% | 52.51-44.2% | 94.07+284.0% | 24.50 |
| Net Property, Plant & Equipment | 33.01-18.7% | 40.61+28.3% | 31.66-10.4% | 35.35+22.1% | 28.95+471.0% | 5.07+0.4% | 5.05+104.5% | 2.47-9.2% | 2.72 |
| Total Investments and Advances | 111.38+38.2% | 80.58+635.9% | 10.95+123.0% | 4.91-92.7% | 67.65 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 9.19+115.7% | 4.26+526.5% | 0.68-37.0% | 1.08+80.0% | 0.600.0% | 0.60-11.8% | 0.68+58.1% | 0.43+330.0% | 0.10 |
| Total Assets | 566.71+1.1% | 560.38+64.9% | 339.89+29.8% | 261.85-25.9% | 353.49+22.6% | 288.33+395.2% | 58.23-40.0% | 96.97+254.9% | 27.32 |
| Short Term Debt Incl. Current Port. of LT Debt | 5.59-0.9% | 5.64+79.0% | 3.15+18.9% | 2.65+115.4% | 1.23 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 11.16+154.2% | 4.39+24.7% | 3.52+6.0% | 3.32-30.3% | 4.76+165.9% | 1.79+2.9% | 1.74+83.2% | 0.95+106.5% | 0.46 |
| Other Current Liabilities | 27.23+42.3% | 19.13+55.7% | 12.29+26.1% | 9.75-5.7% | 10.34-30.9% | 14.96+33.5% | 11.21+57.9% | 7.10+30.3% | 5.45 |
| Total Current Liabilities | 43.98+50.9% | 29.15+53.8% | 18.95+20.5% | 15.73-3.7% | 16.34-2.4% | 16.74+29.2% | 12.96+61.0% | 8.05+36.2% | 5.91 |
| Long Term Debt | 15.82-16.6% | 18.97+64.7% | 11.52-14.5% | 13.47-11.5% | 15.22 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 1.24-25.3% | 1.66+4.4% | 1.59+21.4% | 1.31-53.7% | 2.83-81.4% | 15.20-0.5% | 15.27+12.9% | 13.52-39.9% | 22.49 |
| Total Liabilities | 61.05+22.6% | 49.78+55.3% | 32.06+5.1% | 30.51-11.3% | 34.38+7.6% | 31.94+13.2% | 28.22+30.8% | 21.58-24.0% | 28.40 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 102.980.0% | 102.98+456.3% | 18.51 |
| Common Equity | 505.66-1.0% | 510.61+65.9% | 307.83+33.1% | 231.34-27.5% | 319.11+24.5% | 256.39 | -72.97 | -27.59 | -19.59 |
| Total Shareholders Equity | 505.66-1.0% | 510.61+65.9% | 307.83+33.1% | 231.34-27.5% | 319.11+24.5% | 256.39+754.3% | 30.01-60.2% | 75.39 | -1.08 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 505.66-1.0% | 510.61+65.9% | 307.83+33.1% | 231.34-27.5% | 319.11+24.5% | 256.39+754.3% | 30.01-60.2% | 75.39 | -1.08 |
| Total Liabilities & Stockholders Equity | 566.71+1.1% | 560.38+64.9% | 339.89+29.8% | 261.85-25.9% | 353.49+22.6% | 288.33+395.2% | 58.23-40.0% | 96.97+254.9% | 27.32 |
| Book Value Per Share per share | 8.78-21.3% | 11.15+55.9% | 7.15+0.8% | 7.09-28.4% | 9.90+3.0% | 9.61 | -2.75 | -1.11 | -0.79 |
| Tangible Book Value Per Share per share | 8.78-21.3% | 11.15+55.9% | 7.15+0.8% | 7.09-28.4% | 9.90+3.0% | 9.61 | -2.75 | -1.11 | -0.79 |
| Full-Time Employees people | 196-13.7% | 227+54.4% | 147+5.0% | 140+12.9% | 124+49.4% | 83 | - | - | - |
| Price to Book Ratio ratio | 1.64 | 0.52 | 2.62 | 2.86 | 2.22 | -15.05 | -15.12 | - | - |
| Return on Assets % | -24.86 | -35.74 | -33.52 | -34.94 | -22.22 | -32.72 | -63.54 | -15.37 | - |
| Return on Equity % | -27.57 | -39.31 | -37.40 | -39.06 | -24.78 | -39.59 | -93.56 | -25.71 | - |
| Return on Invested Capital % | -26.87 | -30.38 | -31.58 | -43.91 | -21.33 | -22.11 | -164.30 | -12.67 | - |
| Quick Ratio ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 | 16.88 | 4.05 | 11.68 | 4.15 |
| Current Ratio ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 | 16.88 | 4.05 | 11.68 | 4.15 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | -56.69 | -49.31 | -9.55 |
| Depreciation | - | 7.62+13.6% | 6.71+16.7% | 5.75+48.2% | 3.88+28.5% | 3.02+109.7% | 1.44+44.0% | 1.00+42.9% | 0.70 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | - | 17.23-9.5% | 19.04+2.0% | 18.67+2.2% | 18.27+24.3% | 14.70+191.1% | 5.05-55.4% | 11.33+721.0% | 1.38 |
| Funds from Operations | - | -115.25 | -135.12 | -76.42 | -85.35 | -53.60 | -50.20 | -36.97 | -7.47 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | 6.17+1042.6% | 0.54-14.3% | 0.63 | -1.34 | -15.53 | -0.71-373.1% | 0.26 | -8.78 |
| Cash from Operating Activities | - | -109.08 | -134.59 | -75.79 | -86.69 | -69.13 | -50.91 | -36.71 | -16.25 |
| Capital Expenditures | - | -0.54 | -3.79 | -2.77 | -11.54 | -9.11 | -1.00 | -3.20 | -0.41 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | -92.44 | -298.65-352.0% | 118.49 | -5.51 | -163.57 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | - | -442.82 | -467.65 | -54.80 | -153.31 | -168.57 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | - | 350.38+107.3% | 169.00-2.5% | 173.29+17.2% | 147.80+2856.0% | 5.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | -92.97 | -302.44-361.4% | 115.72 | -17.05 | -172.68 | -1.00 | -3.20 | -0.41 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 112.96-66.5% | 337.25+115.0% | 156.83+4991.9% | 3.08-97.4% | 118.09 | -277.27 | -2.19-102.6% | 84.58 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -278.13 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 112.96-66.5% | 337.25+115.0% | 156.83+4991.9% | 3.08-97.4% | 118.09+13631.4% | 0.86 | -2.19-102.6% | 84.58 |
| Proceedsfrom Stock Options | - | 111.98-66.3% | 332.67+122.5% | 149.52+42620.0% | 0.35-99.7% | 114.73+13240.7% | 0.86 | -2.19-102.6% | 84.58 |
| Issuance or Reduction of Debt, Net | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | - | 112.96-66.5% | 337.25+115.0% | 156.83+4991.9% | 3.08-97.4% | 118.09-57.7% | 278.98 | -2.19-102.6% | 84.58 |
| Net Change in Cash | - | -89.09 | -99.77-150.7% | 196.76 | -100.65 | -123.72-154.5% | 227.07 | -42.11-162.0% | 67.91 |
| Free Cash Flow | - | -109.62 | -138.37 | -78.56 | -98.22 | -78.24 | -51.91 | -39.91 | -16.67 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 375.03+22.9% | 361.33+23.2% | 390.89+21.6% | 402.65-5.2% | 305.06-39.2% | 293.23-45.9% | 321.44-38.9% | 424.88 |
| Short Term Receivables | - | 4.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | - | 17.01+69.1% | 14.47+30.0% | 10.48+4.3% | 7.31-17.6% | 10.06-5.9% | 11.13+15.0% | 10.05 |
| Total Current Assets | - | 382.96+26.3% | 405.36+21.9% | 413.13-5.0% | 312.38-38.8% | 303.29-45.1% | 332.57-37.9% | 434.93 |
| Net Property, Plant & Equipment | - | 28.93-22.1% | 30.94-20.9% | 33.01-18.7% | 35.06-15.8% | 37.15+26.1% | 39.12+27.9% | 40.61 |
| Total Investments and Advances | - | 69.30-44.0% | 66.74-51.3% | 111.38+38.2% | 67.17+37.7% | 123.81+246.6% | 137.00+117.7% | 80.58 |
| Other Assets | - | 11.44+21.8% | 9.86+40.1% | 9.19+115.7% | 9.38+228.0% | 9.39+304.7% | 7.04+814.3% | 4.26 |
| Total Assets | 428.75+1.1% | 492.62+4.0% | 512.90-0.5% | 566.71+1.1% | 423.98-29.8% | 473.64-23.6% | 515.73-18.1% | 560.38 |
| Short Term Debt Incl. Current Port. of LT Debt | - | 5.37-6.1% | 5.49-3.3% | 5.59-0.9% | 5.70+12.0% | 5.72+78.7% | 5.68+79.2% | 5.64 |
| Accounts Payable | - | 12.52+43.9% | 14.69+254.0% | 11.16+154.2% | 6.86+134.9% | 8.70+153.6% | 4.15-1.7% | 4.39 |
| Other Current Liabilities | - | 29.78+47.0% | 23.23+36.1% | 27.23+42.3% | 24.55+14.5% | 20.26+58.5% | 17.07+89.5% | 19.13 |
| Total Current Liabilities | - | 47.67+37.5% | 43.40+61.3% | 43.98+50.9% | 37.11+26.0% | 34.68+78.8% | 26.90+64.0% | 29.15 |
| Long Term Debt | - | 33.84+94.9% | 15.05-17.2% | 15.82-16.6% | 16.57-16.1% | 17.36+66.0% | 18.17+65.2% | 18.97 |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | - | 3.44+384.5% | 2.62+181.7% | 1.24-25.3% | 1.32-29.4% | 0.71-62.8% | 0.93-51.6% | 1.66 |
| Total Liabilities | - | 84.96+61.1% | 61.07+32.7% | 61.05+22.6% | 55.00+7.7% | 52.75+66.0% | 46.01+56.9% | 49.78 |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 337.94-8.4% | 407.66-3.1% | 451.84-3.8% | 505.66-1.0% | 368.98-33.3% | 420.89-28.5% | 469.72-21.8% | 510.61 |
| Total Shareholders Equity | 337.94-8.4% | 407.66-3.1% | 451.84-3.8% | 505.66-1.0% | 368.98-33.3% | 420.89-28.5% | 469.72-21.8% | 510.61 |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 337.94-8.4% | 407.66-3.1% | 451.84-3.8% | 505.66-1.0% | 368.98-33.3% | 420.89-28.5% | 469.72-21.8% | 510.61 |
| Total Liabilities & Stockholders Equity | - | 492.62+4.0% | 512.90-0.5% | 566.71+1.1% | 423.98-29.8% | 473.64-23.6% | 515.73-18.1% | 560.38 |
| Book Value Per Share per share | - | 7.38-18.1% | 8.64-14.8% | 8.78-21.3% | 7.89-25.8% | 9.01-20.5% | 10.14-13.6% | 11.15 |
| Tangible Book Value Per Share per share | - | 7.38-18.1% | 8.64-14.8% | 8.78-21.3% | 7.89-25.8% | 9.01-20.5% | 10.14-13.6% | 11.15 |
| Full-Time Employees people | - | - | - | 196-13.7% | - | - | - | 227 |
| Price to Book Ratio ratio | 1.64 | 1.54 | 1.06 | 0.95 | 0.96 | 0.37 | 0.29 | 0.52 |
| Return on Assets % | -46.99 | -37.09 | -31.28 | -24.86 | -40.70 | -35.87 | -30.80 | - |
| Return on Equity % | -56.68 | -43.25 | -34.92 | -27.57 | -45.38 | -38.87 | -32.97 | - |
| Return on Invested Capital % | - | -16.52 | -14.73 | 3.72 | -14.75 | -12.47 | -9.83 | -9.38 |
| Quick Ratio ratio | - | 8.03 | 9.34 | 9.39 | 8.42 | 8.75 | 12.36 | 14.92 |
| Current Ratio ratio | - | 8.03 | 9.34 | 9.39 | 8.42 | 8.75 | 12.36 | 14.92 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | - | -72.94 | -68.76 | 19.40 | -56.88 | -54.66 | -47.97 | -49.67 |
| Depreciation | - | 2.09+10.6% | 2.06+17.7% | 1.98+11.2% | 2.00+17.6% | 1.89+16.7% | 1.75+10.1% | 1.78 |
| Other Funds (Non Cash) | - | 4.95+30.3% | 3.33-40.9% | 4.42-23.0% | 3.38-21.2% | 3.80+0.8% | 5.63+7.4% | 5.74 |
| Funds from Operations | - | -65.90 | -63.37 | 25.80 | -51.50 | -48.97 | -40.59 | -42.15 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -4.10-173.3% | -4.75 | 2.75 | 5.00-40.9% | 5.59 | -7.17 | -3.72 |
| Cash from Operating Activities | - | -70.00 | -68.12 | 28.55 | -46.50 | -43.38 | -47.76 | -45.86 |
| Capital Expenditures | - | -0.06 | 0.00 | 0.07 | 0.09 | -0.07 | -0.63 | -0.95 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | -0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | 25.61 | 68.88+111.4% | -128.92-1709.5% | 17.69-39.2% | -13.79 | 32.58 | 8.01 |
| Purchase of Investments | - | -62.04 | -33.52 | -178.10 | -15.24 | -115.40 | -134.08 | -57.78 |
| Sale Or Maturity of Investments | - | 87.65-13.7% | 102.40-38.6% | 49.18-25.2% | 32.93-49.2% | 101.62+331.1% | 166.66+1027.6% | 65.79 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | 25.54 | 68.89+115.6% | -128.85-1925.1% | 17.78-34.9% | -13.85 | 31.95 | 7.06 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 23.08+2583.7% | 11.48 | 111.98+18563.3% | 0.12-78.9% | 0.86-95.0% | 0.00-100.0% | 0.60 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 23.08+2583.7% | 11.48 | 111.98+18563.3% | 0.12-78.9% | 0.86-95.0% | 0.00-100.0% | 0.60 |
| Proceedsfrom Stock Options | - | 22.97+2570.9% | 9.81 | 111.12+20103.6% | 0.00 | 0.86-94.8% | 0.00-100.0% | 0.55 |
| Issuance or Reduction of Debt, Net | - | 19.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | - | 19.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 19.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | - | 42.34+4823.3% | 11.48 | 111.98+18563.3% | 0.12-78.9% | 0.86-95.0% | 0.00-100.0% | 0.60 |
| Net Change in Cash | - | -2.12 | 12.25 | 11.69 | -28.60 | -56.37 | -15.81-159.7% | -38.20 |
| Free Cash Flow | - | -70.05 | -68.12 | 28.62 | -46.41 | -43.44 | -48.39 | -46.81 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biological Products, (No Diagnostic Substances) | 0.04 | 85.21 | +230194.6% | 100.0% |
| Total | 0.04 | 85.21 | +230194.6% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Japan | - | 85.00 | - | 99.8% |
| United States | 0.04 | 0.21 | +464.9% | 0.2% |
| Total | 0.04 | 85.21 | +230194.6% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 21.59% | 10.9M | 50.5M | 1.00M |
| 2026-10-15 | 22.84% | 11.5M | 50.5M | 938.72K |
| 2026-09-30 | 22.29% | 11.2M | 50.4M | 902.38K |
| 2026-09-15 | 23.82% | 12.0M | 50.4M | 938.40K |
| 2026-08-31 | 24.10% | 12.1M | 50.1M | 957.52K |
| 2026-08-14 | 24.54% | 12.3M | 50.1M | 843.06K |
| 2026-07-31 | 25.62% | 12.0M | 47.0M | 857.17K |
| 2026-07-15 | 24.21% | 11.4M | 46.9M | 857.91K |
| 2026-06-30 | 28.38% | 13.3M | 46.9M | 851.20K |
| 2026-06-15 | 27.64% | 12.9M | 46.8M | 766.50K |
| 2026-05-29 | 26.14% | 12.2M | 46.6M | 758.48K |
| 2026-05-15 | 25.90% | 12.1M | 46.6M | 737.80K |
| 2026-04-30 | 25.74% | 12.0M | 46.6M | 757.83K |
| 2026-04-15 | 25.32% | 11.5M | 45.5M | 764.20K |
| 2026-03-31 | 23.88% | 10.9M | 45.5M | 787.67K |
| 2026-03-13 | 22.86% | 10.4M | 45.5M | 891.39K |
| 2026-02-27 | 22.29% | 10.1M | 45.5M | 898.71K |
| 2026-02-13 | 21.38% | 9.7M | 45.5M | 899.62K |
| 2026-01-30 | 19.99% | 9.3M | 46.4M | 951.56K |
| 2026-01-15 | 18.23% | 9.5M | 52.0M | 996.36K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 6.00 | 4.30 | 8.50 | 0.00 | 10.456 | 0.00 | 0.00 | 0.888 | -0.139 | 0.003 |
| call | 7.00 | 3.00 | 7.50 | 0.00 | 8.807 | 0.00 | 0.00 | 0.862 | -0.135 | 0.004 |
| call | 8.00 | 2.00 | 6.50 | 0.00 | 7.465 | 0.00 | 0.00 | 0.832 | -0.128 | 0.004 |
| call | 9.00 | 1.20 | 5.50 | 0.00 | 6.320 | 0.00 | 0.00 | 0.795 | -0.119 | 0.005 |
| call | 10.00 | 0.10 | 5.00 | 4.02 | 6.182 | 1.00 | 0.00 | 0.746 | -0.107 | 0.006 |
| call | 11.00 | 0.00 | 5.00 | 0.00 | 6.823 | 0.00 | 0.00 | 0.674 | -0.098 | 0.006 |
| call | 12.00 | 0.00 | 2.60 | 2.58 | 3.649 | 100 | 100 | 0.592 | -0.127 | 0.007 |
| call | 13.00 | 0.00 | 1.60 | 0.20 | 2.758 | 77.00 | 0.00 | 0.536 | -0.146 | 0.007 |
| call | 14.00 | 0.00 | 5.00 | 0.20 | 3.214 | 4.00 | 0.00 | 0.472 | -0.145 | 0.007 |
| call | 15.00 | 0.00 | 5.00 | 0.65 | 3.023 | 18.00 | 0.00 | 0.397 | -0.132 | 0.007 |
| call | 16.00 | 0.00 | 5.00 | 0.00 | 3.353 | 0.00 | 0.00 | 0.375 | -0.144 | 0.007 |
| call | 17.00 | 0.00 | 4.90 | 0.10 | 3.646 | 1.00 | 0.00 | 0.357 | -0.154 | 0.007 |
| call | 18.00 | 0.00 | 5.00 | 0.20 | 3.911 | 10.00 | 0.00 | 0.343 | -0.163 | 0.007 |
| call | 19.00 | 0.00 | 5.00 | 0.80 | 4.151 | 1.00 | 0.00 | 0.332 | -0.171 | 0.006 |
| call | 20.00 | 0.00 | 5.00 | 0.00 | 4.372 | 0.00 | 0.00 | 0.322 | -0.178 | 0.006 |
| call | 21.00 | 0.00 | 5.00 | 0.00 | 4.577 | 0.00 | 0.00 | 0.314 | -0.184 | 0.006 |
| call | 22.00 | 0.00 | 5.00 | 0.00 | 4.767 | 0.00 | 0.00 | 0.307 | -0.190 | 0.006 |
| put | 6.00 | 0.00 | 5.00 | 0.00 | 6.448 | 0.00 | 0.00 | -0.112 | -0.139 | 0.003 |
| put | 7.00 | 0.00 | 5.00 | 0.00 | 5.385 | 0.00 | 0.00 | -0.138 | -0.134 | 0.004 |
| put | 8.00 | 0.00 | 5.00 | 0.00 | 4.476 | 0.00 | 0.00 | -0.168 | -0.127 | 0.004 |
| put | 9.00 | 0.00 | 4.90 | 0.00 | 3.695 | 0.00 | 0.00 | -0.202 | -0.118 | 0.005 |
| put | 10.00 | 0.00 | 5.00 | 0.50 | 2.929 | 2.00 | 0.00 | -0.254 | -0.106 | 0.006 |
| put | 11.00 | 0.00 | 1.00 | 0.70 | 2.224 | 91.00 | 0.00 | -0.326 | -0.097 | 0.006 |
| put | 12.00 | 0.00 | 1.50 | 0.80 | 2.224 | 1.00 | 0.00 | -0.408 | -0.125 | 0.007 |
| put | 13.00 | 0.00 | 4.90 | 0.00 | 6.280 | 0.00 | 0.00 | -0.464 | -0.145 | 0.007 |
| put | 14.00 | 0.00 | 4.90 | 0.00 | 5.233 | 0.00 | 0.00 | -0.528 | -0.144 | 0.007 |
| put | 15.00 | 0.50 | 5.00 | 0.00 | 4.342 | 0.00 | 0.00 | -0.603 | -0.131 | 0.007 |
| put | 16.00 | 1.50 | 6.00 | 0.00 | 4.683 | 0.00 | 0.00 | -0.625 | -0.142 | 0.007 |
| put | 17.00 | 2.50 | 7.00 | 0.00 | 4.989 | 0.00 | 0.00 | -0.643 | -0.152 | 0.007 |
| put | 18.00 | 3.50 | 8.00 | 0.00 | 5.265 | 0.00 | 0.00 | -0.657 | -0.161 | 0.007 |
| put | 19.00 | 4.50 | 9.00 | 0.00 | 5.518 | 0.00 | 0.00 | -0.668 | -0.169 | 0.006 |
| put | 20.00 | 5.50 | 9.90 | 0.00 | 5.606 | 0.00 | 0.00 | -0.678 | -0.176 | 0.006 |
| put | 21.00 | 6.50 | 10.90 | 0.00 | 5.820 | 0.00 | 0.00 | -0.686 | -0.182 | 0.006 |
| put | 22.00 | 7.50 | 11.90 | 0.00 | 6.020 | 0.00 | 0.00 | -0.693 | -0.187 | 0.006 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-10 | SCHEDULE 13G | SEC | ||
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-05 | SEC |
| 2026-10-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-28 | 8-K | Current report | 2026-09-28 | SEC |
| 2026-09-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-16 | SEC |
| 2026-09-16 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-01 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-19 | SEC |
| 2026-08-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-17 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-13 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-04 | SEC |
| 2026-08-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-08-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-20 | 8-K | Current report | 2026-07-18 | SEC |
| 2026-07-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-06-30 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-29 | 8-K | Current report | 2026-06-24 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 774.93K | 2 |
| 2026-09 | 0 | 0 | 841.50K | 3 |
| 2026-08 | 0 | 0 | 1.53M | 5 |
| 2026-07 | 0 | 0 | 737.41K | 2 |
| 2026-06 | 0 | 0 | 1.34M | 3 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 3.36K | 1 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 21.20K | 2 |
| 2025-11 | 0 | 0 | 17.31K | 1 |
Institutional holders
| Manager | % owned |
|---|---|
| Jupiter Topco LLC | 10.99% |
| RA CAPITAL MANAGEMENT, L.P. | 9.66% |
| BlackRock, Inc. | 8.70% |
| GOLDMAN SACHS GROUP INC | 8.15% |
| Novo Holdings A/S | 6.22% |
| BVF INC/IL | 5.51% |
| T. Rowe Price Investment Management, Inc. | 4.81% |
| STATE STREET CORP | 4.47% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.30% |
| Trails Edge Capital Partners, LP | 4.26% |
Funds
| Fund | % owned |
|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3.08% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.04% |
| iShares Russell 2000 ETF | 2.26% |
| Janus Henderson Global Life Sciences Fund | 1.51% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.30% |
| Fidelity Small Cap Index Fund | 0.96% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.88% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.87% |
| iShares Russell 2000 Value ETF | 0.79% |
| Nuveen Quant Small Cap Equity Fund | 0.74% |
OakChart. FDMT. Cached 15 minutes. Terms